{
    "nct_id": "NCT03924856",
    "official_title": "A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)",
    "inclusion_criteria": "* Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%) urothelial histology.\n* Have clinically non-metastatic bladder cancer (N≤1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI)) of the chest/abdomen/pelvis.\n* Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND).\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Have adequate organ function.\n* Male and female participants are eligible to participate if they agree to the contraception use as per study protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a known additional malignancy that is progressing or has required active anti-cancer treatment ≤3 years of study randomization with certain exceptions.\n* Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).\n* Has ≥N2 disease or metastatic disease (M1) as identified by imaging.\n* Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol.\n* Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization or any radiotherapy to the bladder.\n* Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC.\n* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention.\n* Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency virus (HIV) infection, Hepatitis B infection or known active Hepatitis C infection.\n* Has a known psychiatric or substance abuse disorder.\n* Has had an allogenic tissue/solid organ transplant.",
    "miscellaneous_criteria": ""
}